Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study

Roche’s subcutaneous version of its multiple sclerosis (MS) med Ocrevus triumphed in a key late-stage study, likely setting up a new opportunity for the blockbuster drug.

The study, called OCARINA II, evaluated the drug as a twice-yearly, 10-minute subcutaneous injection in patients with relapsing MS (RMS) or primary progressive MS (PPMS). Investigators measured the subcutaneous version against the drug's original intravenous infusion formulation over a 24-week period, enrolling 236 patients in total.